Patents Assigned to GlaxoSmithKline
  • Naphthyridines as integrin antagonists
    Patent number: 10487080
    Abstract: The invention relates to compounds of Formula (I): wherein R1, R2 and R3 are as defined in the description and claims, or pharmaceutically acceptable salts thereof, having ?v?6 integrin antagonist activity. The invention also relates to pharmaceutical compositions including a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and to the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof in therapy, including in the treatment of a disease or condition for which an ?v?6 integrin antagonist is indicated, in particular the treatment of idiopathic pulmonary fibrosis.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: November 26, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Niall Andrew Anderson, Matthew Howard James Campbell-Crawford, Ashley Paul Hancock, Seble Lemma, John Martin Pritchard, Panayiotis Alexandrou Procopiou, Steven Leslie Sollis
  • Oral cleaning implement with a tool adapted for removal of denture adhesive from dentures
    Patent number: 10477957
    Abstract: Aspects of the present invention are directed to an oral cleaning implements having a head and a handle. The implements distal end of the handle may be a tool adapted for removal of denture adhesive from dentures.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: November 19, 2019
    Assignee: GlaxoSmithKline Consumer Healthcare (UK) IP Limited
    Inventors: Marcus James Blachford, Alexander James Brian, Richard Brian Clough
  • Chemical compounds
    Patent number: 10457674
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: October 29, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Niall Andrew Anderson, Nicholas Paul Barton, Sebastien Andre Campos, Edward Paul Cannons, Anthony William James Cooper, Kenneth David Down, Kevin James Doyle, Julie Nicole Hamblin, Graham George Adam Inglis, Armelle Le Gall, Vipulkumar Kantibhai Patel, Simon Peace, Andrew Sharpe, Gemma Victoria White
  • Naphthyridine derivatives useful as alpha-V-beta-6 integrin antagonists
    Patent number: 10450312
    Abstract: A compound of formula (I) or a salt thereof wherein R1 represents a hydrogen atom, a methyl group or a ethyl group R2 represents a hydrogen atom or a fluorine atom R3 represents a hydrogen atom, a methyl group or an ethyl group.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: October 22, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Niall Andrew Anderson, Brendan John Fallon, John Martin Pritchard
  • Pharmaceutical compositions of compound
    Patent number: 10450319
    Abstract: The present invention relates to a salt form of a benzodiazepine derivative, in particular crystalline solid state forms, to pharmaceutical compositions comprising the same and to its use in therapy.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: October 22, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Gossett Augustus Campbell, Asa Elisabeth Gladwin
  • Cyclic di-nucleotides as modulators of STING
    Patent number: 10450341
    Abstract: A compound of formula (1) Or a pharmaceutically acceptable salt and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases and conditions in which modulation of STING (Stimulator of Interferon Genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer and as vaccine adjuvants.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: October 22, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Keith Biggadike, Aurelie Cecile Champigny, Diane Mary Coe, Deborah Needham, Daniel Terence Tape
  • Transient transfection method for retroviral production
    Patent number: 10450574
    Abstract: The invention relates to bacterial artificial chromosomes (BAC) comprising retroviral nucleic acid sequences encoding: gag and pol proteins, and an env protein or a functional substitute thereof, wherein each of the retroviral nucleic acid sequences are arranged as individual expression constructs within the BAC. The invention also relates to uses and methods of transient transfection using said BAC.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: October 22, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Sabine Johnson, Celeste Pallant, Eirini Vamva, Conrad Vink
  • Hydroxy formamide derivatives and their use
    Patent number: 10450288
    Abstract: Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: October 22, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Sarah E. Dowdell, Hilary Schenck Eidam, Mark Elban, Ryan Michael Fox, Marlys Hammond, Mark A. Hilfiker, Tram H. Hoang, Lara Kallander, Brian Griffin Lawhorn, Sharada Manns, Joanne Philp, David G. Washburn, Guosen Ye
  • Benzimidazole derivatives as bromodomain inhibitors
    Patent number: 10442786
    Abstract: Compounds of formula (I) and salts thereof: wherein R1, R2, R3, R4 are defined herein. Compounds of formula (I) and salts thereof have been found to inhibit the binding of the BET family of bromodomain proteins to, for example, acetylated lysine residues and thus may have use in therapy, for example in the treatment of autoimmune and inflammatory diseases, such as rheumatoid arthritis; and cancers.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: October 15, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Rino Antonio Bit, John Alexander Brown, Philip G. Humphreys, Katherine Louise Jones
  • antigenic composition
    Patent number: 10441648
    Abstract: Immunogenic compositions comprising an M72 related antigen, wherein the conductivity of the composition is 13 mS/cm or lower, or the concentration of salts of the composition is 130 mM or lower, and their use in medicine, are provided.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: October 15, 2019
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Stéphane André Georges Godart, Amina Laanan, Dominique Ingrid Lemoine
  • Pyridinone dicarboxamide for use as bromodomain inhibitors
    Patent number: 10428026
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: October 1, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Stephen John Atkinson, Helen Elizabeth Aylott, Anthony William James Cooper, Emmanuel Hubert Demont, Lee Andrew Harrison, Thomas George Christopher Hayhow, Matthew J. Lindon, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • Compounds
    Patent number: 10428078
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: October 1, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Zehong Wan, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E Pero, Christopher Ernst Neipp, Vipulkumar Kantibhai Patel
  • Host cells and methods of use
    Patent number: 10392625
    Abstract: The present invention provides genetically modified Pichia strains wherein at least one nucleic acid sequence encoding a functional gene product and/or at least one nucleic acid sequence necessary for expression of at least one functional gene product in said Pichia strain is genetically modified, wherein said gene product is responsible for proteolysis and/or glycosylation in said genetically modified Pichia strain. In particular, Pichia strains are provided wherein nucleic acid sequence encoding a functional gene product or expression of said gene product are genetically modified: PEP4, PRB1, YPS1, YPS2, YMP1, YMP2, YMP3 and PMT4.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: August 27, 2019
    Assignee: GlaxoSmithKline LLC
    Inventors: Yong Hwan Jin, James D. Jowett, Alexander H. Taylor, Yuan Zhu
  • Package and heat sealing device
    Patent number: 10391717
    Abstract: Aspects of the present invention are directed to a heat sealed packaging wherein the heat seal is along a curved surface. Additional aspects of the present invention are directed to a device for heat sealing a package on a surface that is curved along the direction of force.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: August 27, 2019
    Assignee: GlaxoSmithKline, LLC
    Inventors: Jason R. Crosby, Gautam Debnath, Roger P. Fager, Peter R. Laubmeier, Curtis Emmanuel Stover
  • Compounds as diacylglycerol acyltransferase inhibitors
    Patent number: 10385066
    Abstract: This invention relates to methods for the preparation of a compound which is an inhibitor of acyl coenzyme A: diacylglycerol acyltransferase 1 (DGAT-1).
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: August 20, 2019
    Assignee: GlaxoSmithKline LLC
    Inventors: Mui Cheung, Raghuram Tangirala
  • Vaccines for serogroup X meningococcus
    Patent number: 10376573
    Abstract: A method for immunizing a subject against serogroup X meningococcus by administering a vaccine comprising one, two or all three of: (i) a meningococcal fHbp antigen; (ii) a meningococcal NHBA antigen; and/or (iii) a meningococcal NadA antigen. The vaccine may also include meningococcal outer membrane vesicles.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: August 13, 2019
    Assignees: GlaxoSmithKline Biologicals SA, Institut Pasteur
    Inventors: Mariagrazia Pizza, Peter Dull, Marzia Monica Giuliani, Muhamed-Kheir Taha, Eva Hong, Ala-Eddine Deghmane
  • ISOQUINOLINE DERIVATIVES AS PERK INHIBITORS
    Publication number: 20190241573
    Abstract: The invention is directed to substituted isoquinoline derivatives and uses thereof. Specifically, the invention is directed to compounds according to Formula I and the use of compounds of Formula (I) in treating disease states: wherein R1, R2, R3, R4, R5, R6, R7 and X are as defined herein.
    Type: Application
    Filed: July 18, 2017
    Publication date: August 8, 2019
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Jeffrey Michael AXTEN, Raghava Reddy KETHIRI, Rajendra KRISTAM, Chandregowda VENKATESHAPPA
  • Pyridinone dicarboxamide for use as bromodomain inhibitors
    Patent number: 10370356
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: August 6, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Stephen John Atkinson, Emmanuel Hubert Demont, Lee Andrew Harrison, Thomas George Christopher Hayhow, David House, Matthew J. Lindon, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • Package
    Patent number: D856793
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: August 20, 2019
    Assignee: GlaxoSmithKline Consumer Healthcare Holdings (US) LLC
    Inventors: Gautam Debnath, Jeffrey Scott Brunner
  • Housing for an auto injector
    Patent number: D868244
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: November 26, 2019
    Assignee: GlaxoSmithKline Intellectual Property Management Limited
    Inventors: Mark Anthony Cox, Joseph John Fire, Michelle Nicole Kwasny, Scott Robert Mackie, Robert John McCaffrey, Jason Lee Robinson, Gerd Schmieta